Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.

Khera T, Behrendt P, Bankwitz D, Brown RJP, Todt D, Doepke M, Khan AG, Schulze K, Law J, Logan M, Hockman D, Wong JAJ, Dold L, Gonzalez-Motos V, Spengler U, Viejo-Borbolla A, Ströh LJ, Krey T, Tarr AW, Steinmann E, Manns MP, Klein F, Guzman CA, Marcotrigiano J, Houghton M, Pietschmann T.

J Hepatol. 2019 Apr;70(4):593-602. doi: 10.1016/j.jhep.2018.11.003. Epub 2018 Nov 13.


Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.

Vasiliauskaite I, Owsianka A, England P, Khan AG, Cole S, Bankwitz D, Foung SKH, Pietschmann T, Marcotrigiano J, Rey FA, Patel AH, Krey T.

MBio. 2017 May 16;8(3). pii: e00382-17. doi: 10.1128/mBio.00382-17.


Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity.

Bankwitz D, Doepke M, Hueging K, Weller R, Bruening J, Behrendt P, Lee JY, Vondran FWR, Manns MP, Bartenschlager R, Pietschmann T.

J Hepatol. 2017 Sep;67(3):480-489. doi: 10.1016/j.jhep.2017.04.010. Epub 2017 Apr 22.


Hepatitis C virus plays hide and seek with neutralizing antibodies.

Bankwitz D, Pietschmann T.

Hepatology. 2016 Dec;64(6):1840-1842. doi: 10.1002/hep.28760. Epub 2016 Aug 25. No abstract available.


Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System.

Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T.

J Virol. 2015 Dec 30;90(6):3065-73. doi: 10.1128/JVI.03074-15.


Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Hedenstierna M, Weiland O, Brass A, Bankwitz D, Behrendt P, Uhnoo I, Aleman S, Cardell K, Fryden A, Norkrans G, Eilard A, Glaumann H, Pietschmann T, Sällberg M, Brenndörfer ED.

Aliment Pharmacol Ther. 2015 Mar;41(6):532-43. doi: 10.1111/apt.13096. Epub 2015 Jan 28.


Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese MT, Zeisel MB, Nicosia A, Baumert TF, Kaderali L, Pietschmann T.

J Virol. 2014 Nov;88(21):12644-55. doi: 10.1128/JVI.01145-14. Epub 2014 Aug 20.


Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Lange M, Fiedler M, Bankwitz D, Osburn W, Viazov S, Brovko O, Zekri AR, Khudyakov Y, Nassal M, Pumpens P, Pietschmann T, Timm J, Roggendorf M, Walker A.

PLoS One. 2014 Jul 11;9(7):e102235. doi: 10.1371/journal.pone.0102235. eCollection 2014.


Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P.

Hepatology. 2014 Nov;60(5):1508-18. doi: 10.1002/hep.27196. Epub 2014 Jul 30.


Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly.

Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wölk B, Kaderali L, Pietschmann T.

J Virol. 2014 Feb;88(3):1433-46. doi: 10.1128/JVI.01815-13. Epub 2013 Oct 30.


Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.

Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E.

Gut. 2014 Jul;63(7):1137-49.


Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein.

Westhaus S, Bankwitz D, Ernst S, Rohrmann K, Wappler I, Agné C, Luchtefeld M, Schieffer B, Sarrazin C, Manns MP, Pietschmann T, Ciesek S, von Hahn T.

Hepatology. 2013 May;57(5):1716-24. doi: 10.1002/hep.26190. Epub 2013 Feb 15.


The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.

Zahid MN, Turek M, Xiao F, Thi VL, Guérin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB.

Hepatology. 2013 Feb;57(2):492-504. doi: 10.1002/hep.26097. Epub 2012 Dec 28.


MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles.

Menzel N, Fischl W, Hueging K, Bankwitz D, Frentzen A, Haid S, Gentzsch J, Kaderali L, Bartenschlager R, Pietschmann T.

PLoS Pathog. 2012;8(7):e1002829. doi: 10.1371/journal.ppat.1002829. Epub 2012 Jul 26.


Bile acids specifically increase hepatitis C virus RNA-replication.

Chhatwal P, Bankwitz D, Gentzsch J, Frentzen A, Schult P, Lohmann V, Pietschmann T.

PLoS One. 2012;7(4):e36029. doi: 10.1371/journal.pone.0036029. Epub 2012 Apr 25.


A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes.

Haid S, Novodomská A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, Chhatwal P, Jannack B, Hennebelle T, Bailleul F, Keppler OT, Poenisch M, Bartenschlager R, Hernandez C, Lemasson M, Rosenberg AR, Wong-Staal F, Davioud-Charvet E, Pietschmann T.

Gastroenterology. 2012 Jul;143(1):213-22.e5. doi: 10.1053/j.gastro.2012.03.036. Epub 2012 Mar 27.


Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope.

Ruhl M, Chhatwal P, Strathmann H, Kuntzen T, Bankwitz D, Skibbe K, Walker A, Heinemann FM, Horn PA, Allen TM, Hoffmann D, Pietschmann T, Timm J.

J Virol. 2012 Jan;86(2):991-1000. doi: 10.1128/JVI.05603-11. Epub 2011 Nov 9.


Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.

Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB, Herrmann E, Iken M, Ott M, Baumert TF, Pietschmann T.

PLoS Pathog. 2010 Jul 1;6:e1000978. doi: 10.1371/journal.ppat.1000978.


Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T.

J Virol. 2010 Jun;84(11):5751-63. doi: 10.1128/JVI.02200-09. Epub 2010 Mar 31.

Supplemental Content

Loading ...
Support Center